Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis

doi:10.4254/wjh.v17.i5.105706

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (231)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

151

Figures (1-2)

Tables (1-1)

Sum=207

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=12

May 27, 2025 (publication date) through May 30, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Hepatol. May 27, 2025; 17(5): 105706
Published online May 27, 2025. doi: 10.4254/wjh.v17.i5.105706

Open in New Tab Full Size Figure Download Figure

Figure 1 Forest plot for cardiovascular events in metabolic dysfunction-associated fatty liver disease group compared to non-metabolic dysfunction-associated fatty liver disease group in type 2 diabetes mellitus. MAFLD: Metabolic dysfunction-associated fatty liver disease.

Open in New Tab Full Size Figure Download Figure

Figure 2 Forest plot for prevalence of cardiovascular disease in metabolic dysfunction-associated fatty liver disease group compared to non-metabolic dysfunction-associated fatty liver disease group in type 2 diabetes mellitus. MAFLD: Metabolic dysfunction-associated fatty liver disease.

Citation: Shetty S, Suvarna R, Ambrose Fistus V, Modi S, Pappachan JM. Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis. World J Hepatol 2025; 17(5): 105706
URL: https://www.wjgnet.com/1948-5182/full/v17/i5/105706.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i5.105706